Fig. 5: The in vivo distribution and pharmacokinetics analysis of RDPNs. | Nature Communications

Fig. 5: The in vivo distribution and pharmacokinetics analysis of RDPNs.

From: Supramolecular polyrotaxane-based nano-theranostics enable cancer-cell stiffening for enhanced T-cell-mediated anticancer immunotherapy

Fig. 5

a, c Plasma concentration-time profiles of IR783 and diABZIs post i.v. injection.n = 3 biologically independent animals per group, repeated twice. b The AUC0-t of IR783 and diABZIs analysis. n = 3 biologically independent animals per group, repeated twice. d Quantification of RDPNs in tumor and major organs by fluorescence spectrophotometer. n = 3 biologically independent animals per group. e, g The NIR fluorescence images and the relative fluorescence intensity of tumors in vivo of the 4T1-tumor bearing mice after intravenous injection of NPNs or RDPNs. n = 3 biologically independent animals per group, repeated twice. f, h Ex vivo NIR images and relative fluorescence intensity of different organs. n = 3 biologically independent animals per group, repeated twice. Data were expressed as means ± SD. One-way ANOVA with Tukey’s post hoc test (h) or two-tailed Student’s t-test (b, d). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Back to article page